Is CEMP a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

108 people get CEMP articles and Market Currents by email alert.

Get email alerts on CEMP »

HEADLINES:

Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)

PR Newswire (Mon, 8:00AM)
Cempra Management Discusses Toyama Exclusive Agreement Conference (Transcript)
Wed, May 15
Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan

PR Newswire (May 13, 2013)
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID

PR Newswire (Apr 26, 2013)
Cempra's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results

PR Newswire (Apr 25, 2013)
Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference

PR Newswire (Apr 24, 2013)
Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013

PR Newswire (Apr 18, 2013)
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results

PR Newswire (Feb 28, 2013)
Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Feb 26, 2013)
Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013

PR Newswire (Feb 21, 2013)
Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempra's Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model

PR Newswire (Feb 12, 2013)
Cempra, Inc. to Present at BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference

PR Newswire (Feb 5, 2013)
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
Cempra, Inc. Announces Initiation of Oral Solithromycin Global Phase 3 Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia

PR Newswire (Dec 19, 2012)
Cempra, Inc. Announces Initiation of CEM-102 Phase 2 Clinical Trial in Patients with Prosthetic Joint Infections

PR Newswire (Dec 14, 2012)
Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference

PR Newswire (Dec 5, 2012)
Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London

PR Newswire (Nov 9, 2012)
Cempra, Inc. Reports Third Quarter 2012 Financial and Operating Results

PR Newswire (Nov 8, 2012)

To learn more about Seeking Alpha Pro, click here.

IPO Preview: Cempra Holdings
IPOdesktop • Wed, Feb 1, 2012 • 1 Comment

Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
2 Promising Biopharma Companies To Examine
Matt Schilling • Wed, Aug 1, 2012 • 4 Comments
IPO Preview: Stemline Therapeutics (STML)
IPOdesktop • Tue, Jul 31, 2012 • 2 Comments
IPO Preview: Hyperion Therapeutics
IPOdesktop • Wed, Jul 25, 2012 • 1 Comment
8 IPOs Scheduled For The Week Of July 23
IPOdesktop • Mon, Jul 23, 2012 • 2 Comments
IPO Preview: Durata Therapeutics
IPOdesktop • Wed, Jul 18, 2012
2012 Biotech IPOs: Age Of The Dreamers?
Bioassociate Consulting • Wed, Jul 4, 2012
GAIN Act Should Benefit Antibiotic Makers
Jason Napodano • Wed, Jun 27, 2012 • 3 Comments
Trius Therapeutics: The Calm Before The Storm
Stephen Simpson • Wed, Mar 21, 2012 • 13 Comments
Caesars Stands Out In A Busy IPO Week With Strong Returns
Renaissance Capital IPO Research • Sun, Feb 12, 2012
Troubles For Energy Industry Detract From Exciting Week For U.S. IPOs
Renaissance Capital IPO Research • Mon, Feb 6, 2012
2 Life Sciences IPOs Debut Below Target
The Burrill Report • Sun, Feb 5, 2012
8 U.S. IPOs Planned For The Week
Renaissance Capital IPO Research • Mon, Jan 30, 2012 • 3 Comments
Technology Leads Week With 5 IPO Filings; 5 More Added To Calendar
Renaissance Capital IPO Research • Tue, Jan 17, 2012

Cempra Management Discusses Toyama Exclusive Agreement Conference (Transcript)
Wed, May 15
Cempra's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25

Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)

PR Newswire (Mon, 8:00AM)
Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan

PR Newswire (May 13, 2013)
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID

PR Newswire (Apr 26, 2013)
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results

PR Newswire (Apr 25, 2013)
Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference

PR Newswire (Apr 24, 2013)
Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013

PR Newswire (Apr 18, 2013)
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results

PR Newswire (Feb 28, 2013)
Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Feb 26, 2013)
Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013

PR Newswire (Feb 21, 2013)
Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempra's Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model

PR Newswire (Feb 12, 2013)
Cempra, Inc. to Present at BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference

PR Newswire (Feb 5, 2013)
Cempra, Inc. Announces Initiation of Oral Solithromycin Global Phase 3 Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia

PR Newswire (Dec 19, 2012)
Cempra, Inc. Announces Initiation of CEM-102 Phase 2 Clinical Trial in Patients with Prosthetic Joint Infections

PR Newswire (Dec 14, 2012)
Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference

PR Newswire (Dec 5, 2012)
Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London

PR Newswire (Nov 9, 2012)
Cempra, Inc. Reports Third Quarter 2012 Financial and Operating Results

PR Newswire (Nov 8, 2012)
Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012

PR Newswire (Nov 1, 2012)
Cempra Announces Pricing of $25 Million Private Placement

PR Newswire (Oct 18, 2012)
Cempra, Inc. Continues to Differentiate Solithromycin's Potency and Activity Compared to other Macrolides in Presentations at IDWeek 2012™

PR Newswire (Oct 17, 2012)
Cempra, Inc. Announces Results of Intravenous Solithromycin Phase 1 Study

PR Newswire (Oct 8, 2012)

CEMP vs. ETF Alternatives

Company Description

We are a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Our lead program is CEM-101, which we are... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 12:23 PM Cempra (CEMP -0.2%) fails to get any reaction out of Jefferies' initiating coverage today with a Buy rating and $10 price target. The firm cites optimism over its pipeline, saying that its lead drug solithromycin is the key value driver. However, the company has limited capital, which has impacted its ability to conduct Phase 3 trials in an expedited manner. It will likely need to secure additional financing to further advance its programs, leaving the the stock with a potential dilutive overhang. Comment! [Healthcare]
Friday, May 17, 10:22 AM Jefferies starts Cempra Holdings (CEMP +2.5%) at Buy with a $10 price target. Comment! [Healthcare]
Thursday, April 25, 6:46 PM Cempra (CEMP): Q1 EPS of -$0.42 misses by $0.07. (PR) Comment! [Earnings, Breaking News]
Monday, March 11, 6:40 AM Cempra Holdings (CEMP) files a registration statement with the SEC for the right to sell a mix of $100M worth of securities. (S-3) Comment! [Healthcare]
Thursday, February 28, 5:17 PM Cempra (CEMP): Q4 EPS of -$0.26 beats by $0.06. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, October 19, 2012, 12:45 PM Midday top 10 gainers: GURE +18%. RVBD +13%. CALL +12%. EFUT +10%. MAN +9%. NCTY +9%. FWRD +8%. USCR +8%. XIN +7%. CCIH +6%.
Top 10 Losers: CBLI -24%. PXLW -22%. MIG -21%. ZIOP -17%. VOC -15%. CMG -15%. MRVL -14%. AMD -14%. BGMD -14%. CEMP -13%. Comment! [On the Move]
Friday, February 3, 2012, 11:15 AM Cempra (CEMP) trades at $6.20 after the clinical-stage pharmaceutical firm priced its IPO at $6 - a mark that stands well-below the initial range of $11-$13. A quick early check on the 2012 IPO market shows filings are up Y/Y and newly minted companies have returned 7.4% from their offering prices. Comment! [Healthcare]

CEMP Cempra Holdings

CEMP

Cempra Holdings